Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04753203 | Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients(ALCAP) | unknown | Phase 1 / Phase 2 | 65 | Korean Cancer Study GroupOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06107894 | TIL Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 | 12 | NeogenTCINDUSTRY | 0 | Oct 30, 2023 | clinicaltrials |
| NCT06011291 |
| A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer |
| unknown |
| Phase 1 |
| 73 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY |
| 1 |
| Oct 27, 2023 |
| clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Oct 25, 2023 | clinicaltrials |
| NCT06056752 | QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05716919 | Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule | unknown | Phase 1 | 32 | Machaon Biotherapeutics, Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092268 | A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 270 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06095674 | ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study(ITHACA) | unknown | Phase 1 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT03129139 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors(Minnelide 101) | unknown | Phase 1 | 66 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05263180 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | unknown | Phase 1 | 30 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Oct 18, 2023 | clinicaltrials |
| NCT05566834 | Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06088459 | NWRD06 DNA Plasmid for HCC After Radical Resection | unknown | Phase 1 | 9 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06083701 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | unknown | Phase 1 / Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06081322 | A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors(CISPD-5) | unknown | Phase 1 | 29 | Zhejiang UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06082570 | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06078670 | PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 96 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06078800 | A Study of YL-17231 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 80 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06078982 | Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer | unknown | Phase 1 | 39 | Shanghai East HospitalOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06080984 | The Application of Novel Oncolytic Virus in Late Stage Solid Tumors | unknown | Phase 1 | 24 | West China HospitalOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04303403 | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | unknown | Phase 1 | 48 | National Cancer Centre, SingaporeOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04546074 | Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | unknown | Phase 1 / Phase 2 | 22 | Keio UniversityOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04712864 | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | unknown | Phase 1 | 50 | Legend Biotech USA IncINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT06062355 | Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer | unknown | Phase 1 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Oct 2, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04693676 | A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma | unknown | Phase 1 | 17 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05352646 | NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 1 | 26 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05267899 | A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 24 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06049030 | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma | unknown | Phase 1 | 190 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06054932 | Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors | unknown | Phase 1 | 18 | Beijing Likang Life Science and Tech Co., Ltd.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06049667 | A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies | unknown | Phase 1 | 72 | Nanjing Chia-tai Tianqing PharmaceuticalINDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04979611 | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | unknown | Phase 1 | 60 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | unknown | Phase 1 / Phase 2 | 15 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06006338 | 3D Printed Models for Liver Surgery | unknown | Phase 1 | 5 | Zhejiang Cancer HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06047431 | A Study of QL1706H in Patients With Advanced Solid Tumors | unknown | Phase 1 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT06041035 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03709914 | PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)(Pediatric_PK) | unknown | Phase 1 | 21 | Nabriva Therapeutics AGINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06008366 | A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 281 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 31, 2023source: clinicaltrials